April 13, 2016
Amniox Medical’s Neox®1K is the First Cryopreserved Umbilical Cord Allograft that Can Be Safely Refrigerated for Two Years
ATLANTA – April 13, 2016 – Amniox Medical, Inc., a TissueTech, Inc. company, announced at the Spring Symposium on Advanced Wound Care in Atlanta that the company’s proprietary CryoTek® Cool Storage Technology now delivers the first cryopreserved umbilical cord allograft that can be safely refrigerated for as long as two years without compromising the structural or functional integrity of the tissue. When compared to amniotic membrane alone, Neox 1K is a more potent, more persistent umbilical cord allograft that is indicated for the treatment of chronic wounds.
“Now Neox tissue can be safely refrigerated for an extended period, delivering tremendous ease of use to clinicians,” said Thomas J. Dugan, CEO of Amniox. “Our goal is to provide an allograft that is not only underpinned by substantial science and clinical study but also allows providers to improve the care they deliver to patients and fits into their practices easily. CryoTek-processed umbilical cord and amniotic membrane are proven to be biologically superior to dehydrated options. In addition to this biological superiority, ours is the only cryopreserved option that does not require storage in a deep freezer.”
Under an extended two-year shelf life, Neox can be stored safely at temperatures ranging from -112º F to 39º F. The tissue also offers extended six-hour room temperature stability: intact product can be exposed to ambient temperatures for up to six hours and then safely returned to cold temperature storage if unused. Other available cryopreserved amniotic membrane products must be discarded if not used within an hour of being exposed to room temperature. Furthermore, easier thawing requirements allow Amniox products to simply be exposed to room temperature prior to use, without the use of special equipment and supplies required by other available technologies.
CryoTek Cool Storage Technology is a patented process that is backed by more than 25 years of National Institute of Health-supported research into amniotic membrane and umbilical cord biology. The integrity of the allograft is preserved and the process is scientifically proven to maintain the innate structural and biological properties of the tissue.
Amniox parent TissueTech pioneered the clinical application of human umbilical cord and amniotic membrane to promote rapid, scarless healing that occurs in utero to wounds in adults. Since the company’s inception, more than 200,000 human transplants of its products have been performed and more than 300 peer-reviewed studies supporting its technology platform have been published. Amniox Medical was formed in 2011 to focus on the orthopedic and wound care markets.
About Amniox Medical, Inc.
Founded in 2011 to serve the orthopedic and wound care markets, Amniox Medical is dedicated to developing and marketing regenerative therapies processed from umbilical cord and amniotic membrane utilizing its proprietary CryoTek technology. This process has been proven to preserve the innate biological and structural properties of the matrix, which can then be transplanted to adult wound and surgical environments. Amniox Medical procures its tissue through elective donation following healthy live birth via Cesarean section. Thorough donor screening is performed to ensure the safety of its products. For additional information, please visit http://www.biotissue.com.
About TissueTech, Inc.
TissueTech, Inc., the parent company of Amniox Medical, Inc. and BioTissue, Inc., pioneered the development and clinical application of regenerative, amniotic tissue-based products. Amniox Medical develops and markets products for use in the musculoskeletal and wound care markets; BioTissue develops and markets products for the ophthalmology and optometry markets. The National Institutes of Health (NIH) has supported TissueTech’s research with more than 25 continuous years of research grants. Since the company’s inception, clinicians have performed more than 200,000 human implants of the company’s products and published more than 300 peer-reviewed studies supporting its technology platform. The Company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.